NEW YORK, Sept. 11 – Quark Biotech said Tuesday that Mitsubishi-Tokyo Pharmaceuticals of Japan has made an equity investment in the company of an undisclosed amount.

Quark and Mitsubishi-Tokyo, a wholly owned subsidiary of Mitsubishi Chemical Corporation, are currently collaborating to develop drug targets for neurodegenerative diseases as well as other disease areas.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.